Artax Biopharma, Inc.
Last verified 2026-05-06. JSON
| Total raised | $19.0M |
|---|---|
| Latest round | Funding round, $19.0M, 2024-07-31 |
| Founded | unknown |
| Headquarters | Cambridge, MA |
| Industry | pharma |
| Stage | unknown |
| Website | artaxbiopharma.com |
Artax Biopharma develops oral small-molecule Nck modulators that dampen inappropriate T-cell activation at the TCR signaling level without globally suppressing the immune system. It targets autoimmune diseases including psoriasis, atopic dermatitis, and rheumatoid arthritis. Lead asset AX-158 is a first-in-class Phase 2 program modulating Signal 1 instead of downstream cytokines.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-07-31 | Funding round | $19.0M | undisclosed |
Detected tech stack
Nginx, jQuery Migrate 3.4.1, Complianz, WordPress Block Editor, WordPress Site Editor, PHP, MySQL, wordpress ., jquery 3.7.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $19.0M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Total raised $19.0M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Company existence | self-reported | artaxbiopharma.com, read 2026-05-06 |
| Description | self-reported | artaxbiopharma.com, read 2026-05-06 |
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $19.0M, 2024-07-31 → Funding round, $19.0M, 2024-07-31, SEC EDGAR, document, retrieved 2026-09-25 | Latest round | seed, $19.0M, 2024-07-31 → Funding round, $19.0M, 2024-07-31 | SEC EDGAR, document, retrieved 2026-09-25 |
| 2026-09-25Round: attributed → sourced, SEC EDGAR, document, retrieved 2026-09-25 | Round | attributed → sourced | SEC EDGAR, document, retrieved 2026-09-25 |
Records begin 2026-09-24. All changes